[go: up one dir, main page]

WO2020084456A1 - Timbre intelligent - Google Patents

Timbre intelligent Download PDF

Info

Publication number
WO2020084456A1
WO2020084456A1 PCT/IB2019/058967 IB2019058967W WO2020084456A1 WO 2020084456 A1 WO2020084456 A1 WO 2020084456A1 IB 2019058967 W IB2019058967 W IB 2019058967W WO 2020084456 A1 WO2020084456 A1 WO 2020084456A1
Authority
WO
WIPO (PCT)
Prior art keywords
user
intake
data
time
cannabinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2019/058967
Other languages
English (en)
Inventor
Michael CABIGON
Jim SEETHRAM
Steven Splinter
Denis TASCHUK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radient Technologies Innovations Inc
Original Assignee
Radient Technologies Innovations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radient Technologies Innovations Inc filed Critical Radient Technologies Innovations Inc
Publication of WO2020084456A1 publication Critical patent/WO2020084456A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
    • A61B5/0022—Monitoring a patient using a global network, e.g. telephone networks, internet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/14517—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for sweat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4845—Toxicology, e.g. by detection of alcohol, drug or toxic products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/008—Electronic counters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0061—Methods for using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3303—Using a biosensor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3546—Range
    • A61M2205/3553—Range remote, e.g. between patient's home and doctor's office
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • A61M2205/3592—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using telemetric means, e.g. radio or optical transmission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502—User interfaces, e.g. screens or keyboards
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/08—Supports for equipment
    • A61M2209/088—Supports for equipment on the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user

Definitions

  • the present disclosure is generally related to monitoring cannabis usage with a wearable device that can deliver at least one cannabinoid to the user based on user preference and / or a treatment plan.
  • Cannabis is becoming increasingly available to the public for medicinal and social use.
  • a plethora of cannabis products have flooded and continue to enter the market.
  • Consumers of cannabis are faced with various forms of products and delivery methods, such as smoking dried flower, vaping liquids for inhalation, and utilizing extracts and concentrates for oral, nasal and transdermal administration.
  • users may test various different strains or delivery methods in small and ever increasing doses. The difficulty of finding a match is further compounded by the inaccuracy of product labels on the product package.
  • FIG. 1 illustrates an exemplary network environment in which a system for automated cannabinoids usage through a wearable device may be implemented.
  • FIG. 2 is a flowchart illustrating an exemplary method for controlling automated user dosage using a wearable device.
  • FIG. 3 is a flowchart illustrating an exemplary method for adjusting user preference of desired cannabis dosages.
  • FIG. 1 is a block diagram illustrating an exemplary system 100 for automated cannabinoids usage through a wearable device.
  • This system 100 may include a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102, a testing network 102,
  • the communication network 112 may be the cloud or internet that connects and enable communication between the label network 102, user device 114, intake device 120, and smart patch 122.
  • the testing network 102 collects usage data from any intake devices 120 and data collected from the smart patch 122.
  • the testing network 102 uses the received data to make determinations on the release of drug compounds through the smart patch to keep the user's levels within a desired range during consumption events.
  • the testing network 102 may include a user database 104, a testing database 106, a usage database 108, and a
  • the user database 104 may store information about the user of the system.
  • User information may include the user's treatment plan, medical information, physical ailments, data related to any intake device 120, data related to any smart patch 122, and the user device 114.
  • the testing database 106 stores information provided by the smart patch 122.
  • the smart patch 122 may detect analytes (e.g., cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD)) in the sweat of the user. A separate step of swabbing and testing the user sweat is unnecessary.
  • analytes e.g., cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD)
  • THC tetrahydrocannabinol
  • CBD cannabidiol
  • Information stored in the testing database may include a timestamp, whether cannabinoids were detected, and related information such as the amount and type of cannabinoids detected.
  • the usage database 108 may contain information related to the user's cannabis usage from any intake device 120, smart patch 122, and user input from the user device 114.
  • the usage database 108 may catalog each user's cannabis consumption history. Each consumption event documented may also include the cannabis strain, quantity used, and user feedback.
  • the recommendation module 110 analyzes an aggregate of data received by the testing network 102, in order to provide a recommendation to the user and executable instruction to the smart patch 122.
  • the recommendation module 110 may analyze the amounts of cannabinoids tested in the user. New data received from the testing database 106 may trigger the activation of the recommendation module 110.
  • the recommendation module 110 may compare the levels of cannabinoids detected in the user's system to the user- configured treatment plan.
  • the testing database 106 may have received data from the smart patch 122 regarding the relative amounts of THC and CBD in the user's sweat.
  • the recommendation module 110 may compare the reported relative amounts to the preset treatment plan of the user and control the administration of at least one other cannabinoid by the smart patch 122.
  • the communication network 112 may include wired and wireless network. If wireless, the communication network 112 may be implemented using communication techniques such as visible light communication (VLC), worldwide interoperability for microwave access (WiMAX), long term evolution (LTE), wireless local Area network (WLAN), infrared (IR) communication, public switched telephone network (PSTN), radio waves, near field communication (NFC), and other communication techniques known in the art.
  • VLC visible light communication
  • WiMAX worldwide interoperability for microwave access
  • LTE long term evolution
  • WLAN wireless local Area network
  • IR infrared
  • PSTN public switched telephone network
  • NFC near field communication
  • the communication network 112 may allow ubiquitous access to shared pools of configurable system resources and higher-level services that can be rapidly provisioned with minimal management effort.
  • the communication network 112 is often a network in the Internet and may rely on sharing of resources with outside networks to achieve coherence and economies of scale.
  • the user device 114 may be a laptop, smartphone, tablet, smart watch, or any personal computer device that may facilitate the collection of data from the intake device 120 and the wearable device such as the smart patch 122. Data from the user device 114 may be transmitted to the testing network 102 via the usage application 116.
  • the usage application 116 is software downloaded onto the user device 114 that may allow the user to track the user's cannabis usage and its effects.
  • the usage application 116 may allow the user to specify their preferences for the consumption events with specific types of cannabis products or products with specific traits.
  • the user's regular treatment plan calls for a 1:1 ratio of THGCBD as the effective therapeutic dose to control pain.
  • the user can specify the duration (e.g., all day or temporary for two hours) and the degree (e.g., peak THC:CBD ratio of 15:1). If the user provides no input, the system works to keep them in the default effective dose range automatically.
  • the preference database 118 stores the user-configured settings per consumption event. For example, the user may have stored in the preference database 118 an event with the preset of duration of 2 hours of 15:1 THGCBD ratio when consuming an Indica strain with at least 20% THC.
  • the preference database 118 may be selected and activated by the user to allow the recommendation module to automate the release of compounds via the smart patch 122.
  • the intake device 120 may include any other non-smart patch device that allows user to intake cannabinoids.
  • the intake device 120 may be connected via a communication network 112 to the user device and testing network 102 such that the release of cannabinoids from the intake device 120 is monitored and controlled.
  • Examples of intake non-wearable devices may include a vaporizing device that vaporizes cannabis product to be inhaled by the user.
  • a vaporizing device may also be an aerosol inhaler device.
  • the vaporizer may transmit the amount consumed wirelessly to the user device 114 and the testing network 102 to the stored in the usage database 108.
  • the intake device 120 may not be able to connect with the testing network.
  • user may manually report the intake device and corresponding cannabinoid usage via the user application 116. Any reported usage is transmitted and stored in the usage database 106 of the testing network 102.
  • the testing network 102 may be connected to multiple intake devices 120 with each intake device 120 sending its relative data to the usage database 108.
  • the smart patch 122 is a wearable device by a user.
  • the term "smart patch” is used to indicate a general class of wearable devices that allows automated control over the release and monitoring of cannabinoids, without additional user action, after the device has been programmed by the user and attached to the user.
  • the smart patch 122 may contain a communication module 124, a delivery actuator 126, and a drug reservoir 128.
  • the smart patch 122 is an actual patch that can adhere to the surface of the user's skin.
  • the smart patch 122 may be a triboelectric energy harvester patch.
  • the delivery actuator 126 of the smart patch 122 may be a drug delivery system with a pump that may be coupled with a bendable microneedle skin patch.
  • the drug reservoir 128 may store at least one cannabinoid.
  • the microneedle and triboelectric patches may be coupled to multiple dry adhesive patches to enable the entire wearable device to adhere onto the curved skin surface.
  • the drug reservoir 128 may be connected to the delivery actuator 126.
  • the reservoir 128 may be located on backside of the microneedle patch of the delivery actuator 126.
  • the delivery actuator 126 may trigger the release of the drug in the reservoir and control the drug delivery upon skin penetration.
  • the communication module 124 may deliver information regarding the absorbed cannabinoid to the user device 114 and the testing network 102.
  • FIG. 2 is a flowchart illustrating an exemplary method 200 for controlling automated user dosage using a wearable device.
  • the recommendation module 110 may receive new data event from testing database 106 at step 202.
  • the user may configure the system to a two-parameters testing system, where the two parameters are CBD and THC.
  • the recommendation module 110 may query the user database 104 for the user's treatment plan at step 204.
  • the user's treatment plan may detail the desired effective CBD:THC ratio.
  • the recommendation module 110 may query the usage database 108 for a consumption event in the last 120 minutes.
  • a consumption event may be the use of a cannabis product through the intake device, the wearable device, and other usage that the user has reported through the user device 114.
  • the usage database 108 may receive and save the usage event including related data such as timestamp, amount in milligram of consumed product, THC and CBD percentages, etc..
  • the recommendation module 110 may determine if the CBD:THC ratio in the current testing data is within the effective dose range at step 208. If the CBD:THC ratio in the current testing data is within the effective dose range, then the recommendation module 110 may stop its analysis and poll for new data event in the testing database 106 at step 222.
  • the recommendation module 110 may determine if there was a consumption event in the effective time period at step 210.
  • the effective time period may be 2 hours. The user may configure the system to an effective time period of their preference or in accordance with a preset treatment plan.
  • the recommendation module 110 will calculate the CBD or THC dose necessary to reach the effective dose range at 216. However, if there was a consumption event at this juncture of the monitoring, then the recommendation module 110 pause its inquiry to allow the usage database 108 to update the data regarding the consumption effect (e.g., the cannabis strain and amounts) at step 212.
  • the consumption effect e.g., the cannabis strain and amounts
  • the data supplied will include quantity of consumption and attributes of the product, such as THC and CBD percentages, Sativa versus Indica dominance, etc.
  • the recommendation module 110 may query the usage application 116 on the user device 114 to determine whether the user will configure a new desired effective dose at step 214.
  • the effective dose preferences or desired effective dose is a configurable dosage amount that is configured by the user.
  • the user may specify the length of time and the level of "high" or pain relief that they wish to experience.
  • the effective dose range may be configured by the user at various times.
  • the user may activate a saved preference in the preference database 118 and transmit that preference to the testing network 102.
  • a 1:1 ratio of THC to CBD has been shown to have a therapeutic effect in pain relief in chronic cancer patients.
  • the recommendation module 110 may release cannabinoids from the smart patch 122 continuously at the 1:1 ratio and monitor the user via the smart patch 122 to ensure the 1:1 ratio is maintained.
  • THC provides psychoactive effects that some users desire and the user may indicate temporary preference for higher dosage of THC.
  • CBD may also be used to balance the psychoactive effects of THC to maintain the specified preference.
  • a user may want to feel the psychoactive effects of the THC when they utilize the intake device 120 for a preset period of time.
  • the recommendation module 110 may activate the patch 122 to releases CBD into the bloodstream to bring down that high and return the user to the desired effective dose range specified in their treatment plan.
  • a user may have the option to tailor the preferred effective dose range to each life event. For example, the user may have saved a preset preference for higher THC ratios for parties but another saved preference for higher CBD ratios that may be suitable for deeper sleep.
  • the recommendation module 110 may calculate the CBD dose needed to reach the effective dose range at step 216. Once the amount of CBD is calculated in step 216, the recommendation module 110 may poll the wearable device 122 to see if the needed dose is available in the drug reservoir 128 at step 218. If there are insufficient amounts, the recommendation module 110 may notify the user to refill the reservoir 128 at step 220. In an embodiment, the user may communicate through the usage application 116 that the user will consume the needed dose outside of the wearable device 122 or through the intake device 120. The user may also accept or select a different preference dose. If the reservoir 128 contains the calculated dose, then recommendation module 110 may release the calculated CBD dose according to the user selected preferences at step 222. The
  • recommendation module 110 may continuously poll the testing database for a new data to monitor the levels of cannabinoids in the user at step 222. The process continually repeats at step 202.
  • the user has consumed 20 mg of 20% THC and 1% CBD.
  • the user has indicated their user preference via the usage application 116 to set a maximum duration of two hours and a maximum THGCBD ratio of 15:1.
  • the default therapeutic level as specified in the user's treatment plan is a ratio 1:1.
  • the recommendation module 110 may calculate a CBD amount of necessary to keep the user under 15:1 ratio for the duration of the 120 minutes.
  • the recommendation module 110 may then activate the smart patch 122 to release the calculated amount.
  • the recommendation module 110 will analyze the data in the testing database 106 and the usage database 108, to calculate the amount of CBD to bring the ratio down to 1:1, the default preference.
  • the user may have consumed 4 mg of THC and 0.2 mg of CBD. If the user was a perfect processor the THGCBD ratio in the testing data would be 20:1, but users metabolize cannabinoids at different rates. The testing data in this example shows 17:1 ratio in the user's sweat. So rather than needing the 3.8 mg of CBD to make up the difference, the system need only output 85% of that, or 3.23 mg of CBD.
  • the testing data in this example shows 17:1 ratio in the user's sweat. So rather than needing the 3.8 mg of CBD to make up the difference, the system need only output 85% of that, or 3.23 mg of CBD.
  • recommendation module 110 will then deliver only the 3.23 mg of CBD to bring the user down to the 15:1 ratio specified in the user preference data.
  • FIG. 2 illustrates a continuous process of monitoring and cannabinoid adjustment that may be triggered with each new data that enters the testing database in order to maintain a preference level.
  • the math will change when the 120 minutes after the consumption event is met, as the system will be reset back to a default preference such as the 1:1 therapeutic dose again as opposed to the 15:1 temporary preference. .
  • FIG. 3 is a flowchart illustrating an exemplary method 300 to adjust user preference of desired cannabis dosages.
  • the usage application 116 of the user device 114 may receive data that the user has consumed cannabis at step 302.
  • the usage application 116 may receive this data from the smart patch 122, the intake device 120, or from user's manual input.
  • the usage application 116 may identify the strain and related data at step 304.
  • Related data identified may include quantity of product consumed and percentages of product constituents like THC and CBD.
  • the user may have consumed 20 mg of "Strain A" cannabis that has been identified to contain 20%THC and 1% CBD.
  • the application 116 may prompt the user to provide strain based alterations to their treatment plan at step 306.
  • Example alteration may include preferences in maximum allowable THC:CBD ratio, and the duration of the "high" desired.
  • the user may set 2 hours as their maximum desired effective duration of THC-induced psychoactive effects with a maximum desired THC:CBD ratio of 15:1.
  • the usage application 116 may then save the user preferences to the preferences database at step 308.
  • the usage application 116 may then poll for a prompt from the recommendation module 110 at step 3010.
  • the usage application 116 may then receive a prompt from the recommendation module 110 that new testing data has been received in the testing database 106 at step 310.
  • the usage application 116 may then offer the user to take manual control of the specific consumption experience at step 314.
  • the usage application 116 may wait to receive confirmation of whether the user opts for manual control of their experience within a time limit (e.g., two minutes) at step 316. If the user selects the manual control option within the time limit, the user will be offered the same type of prompts as received in step 306.
  • a time limit e.g., two minutes
  • the usage application 116 may then query the preference database 118 for user defined preferences for the strain identified by the intake device 120 at step 318.
  • the usage application 116 may send the preferences back to the recommendation module 110 at step 320.
  • the preference sent back to the recommendation module 110 may be the preference indicated in the preference database 118, the preference indicated by user manual inputs, or a NULL message.
  • the usage application 116 may poll for a prompt of a consumption event at step 322. This process is an automated continuous process triggered by data of new cannabis usage.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Databases & Information Systems (AREA)
  • Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé d'utilisation d'un timbre intelligent, doté de capacités de test d'analyte, permettant de tester la sueur d'un porteur pour les teneurs de divers cannabinoïdes et de distribuer au moins un autre cannabinoïde à l'utilisateur à partir d'un réservoir dans le timbre, afin de maximiser les effets thérapeutiques en fonction des préférences de l'utilisateur. Un utilisateur possède un plan de traitement comportant une dose efficace. Le timbre teste la sueur de l'utilisateur et, lorsque la teneur dépasse la plage thérapeutique, libère la quantité correcte du cannabinoïde dans le réservoir afin de revenir à la plage thérapeutique, ou à une plage différente spécifiée par l'utilisateur dans le cadre de l'événement de consommation d'un produit de cannabis par l'intermédiaire d'un vaporisateur connecté.
PCT/IB2019/058967 2018-10-24 2019-10-22 Timbre intelligent Ceased WO2020084456A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862750208P 2018-10-24 2018-10-24
US62/750,208 2018-10-24

Publications (1)

Publication Number Publication Date
WO2020084456A1 true WO2020084456A1 (fr) 2020-04-30

Family

ID=70331376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/058967 Ceased WO2020084456A1 (fr) 2018-10-24 2019-10-22 Timbre intelligent

Country Status (1)

Country Link
WO (1) WO2020084456A1 (fr)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784364B2 (en) * 2008-09-15 2014-07-22 Deka Products Limited Partnership Systems and methods for fluid delivery
US20150287122A1 (en) * 2014-04-08 2015-10-08 White Shelf Research, LLC. Consumable personalization
US20160220798A1 (en) * 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
US20160370337A1 (en) * 2015-06-16 2016-12-22 Lunatech, Llc Analysis System For Biological Compounds, And Method Of Operation
WO2017118980A1 (fr) * 2016-01-06 2017-07-13 Syqe Medical Ltd. Traitement thérapeutique à faible dose
WO2017122201A1 (fr) * 2016-01-11 2017-07-20 Syqe Medical Ltd. Procédé et système de commande d'administration de principes actifs
US20170266397A1 (en) * 2016-03-21 2017-09-21 Advanced Grow Labs, Llc Vaporizing device system and method
WO2017205692A1 (fr) * 2016-05-25 2017-11-30 Pax Labs, Inc. Commande d'un vaporisateur électronique
US20180039741A1 (en) * 2016-08-02 2018-02-08 George Trudell, JR. Mobile system and method for monitoring and/or leveraging cannabinoid levels in the blood of a user
US20180060518A1 (en) * 2016-08-25 2018-03-01 Christine R. Pappas Electronic community medical marijuana network

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784364B2 (en) * 2008-09-15 2014-07-22 Deka Products Limited Partnership Systems and methods for fluid delivery
US20150287122A1 (en) * 2014-04-08 2015-10-08 White Shelf Research, LLC. Consumable personalization
US20160220798A1 (en) * 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
US20160370337A1 (en) * 2015-06-16 2016-12-22 Lunatech, Llc Analysis System For Biological Compounds, And Method Of Operation
WO2017118980A1 (fr) * 2016-01-06 2017-07-13 Syqe Medical Ltd. Traitement thérapeutique à faible dose
WO2017122201A1 (fr) * 2016-01-11 2017-07-20 Syqe Medical Ltd. Procédé et système de commande d'administration de principes actifs
US20170266397A1 (en) * 2016-03-21 2017-09-21 Advanced Grow Labs, Llc Vaporizing device system and method
WO2017205692A1 (fr) * 2016-05-25 2017-11-30 Pax Labs, Inc. Commande d'un vaporisateur électronique
US20180039741A1 (en) * 2016-08-02 2018-02-08 George Trudell, JR. Mobile system and method for monitoring and/or leveraging cannabinoid levels in the blood of a user
US20180060518A1 (en) * 2016-08-25 2018-03-01 Christine R. Pappas Electronic community medical marijuana network

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN W, TIAN R, XU C ET AL.: "Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy", NATURE COMMUNICATIONS, vol. 8, no. 1, 24 November 2017 (2017-11-24), pages 1 - 11, XP055710786 *
VOSS, ANDREAS ET AL.: "Detecting cannabis use on the human skin surface via an electronic nose system", SENSORS, vol. 14, no. 7, 2014, pages 13256 - 13272, XP055710797 *
YU J ET AL.: "Bioresponsive transcutaneous patches", CURR OPIN BIOTECHNOL, 2017, pages 4828 - 32, XP085252992 *

Similar Documents

Publication Publication Date Title
JP6851532B2 (ja) 治療薬剤注入器機を制御するハンドセット機との間の送受信の管理
US10293101B2 (en) Diabetes management system
US10987032B2 (en) Method, system, and apparatus for remotely controlling and monitoring an electronic device
AU2022200137A1 (en) Data backfilling for continuous glucose monitoring
US20200373009A1 (en) Therapeutic product delivery system and method of pairing
US10213547B2 (en) Safety processor for a drug delivery device
US20210244883A1 (en) Infusion pump assembly and method
US9813985B2 (en) Handset device
EP2217135B1 (fr) Evaluation d'un temps d'insuline résiduelle
US20170351840A1 (en) Wearable kit with smart patch
US20090326516A1 (en) Preparatory dispensation systems and methods
US20180144033A1 (en) Information processing device
WO2015187738A1 (fr) Appareil de pompe à insuline, dispositif, méthodologie et trousse
JP2010533027A (ja) ポンプ切断中の血糖管理システムおよび方法
WO2020084456A1 (fr) Timbre intelligent
EP3586338A1 (fr) Systèmes et procédés permettant de communiquer une dose
JP2019532391A (ja) インスリン投薬計画における基礎／ボーラス比を調節するためのシステムおよび方法
US11311668B2 (en) Auto-calibration of physiological response estimates for closed-loop insulin delivery using patient-selected standardized meals
US20200155789A1 (en) System and method for determining the efficacy of music therapy
US20230088267A1 (en) Dual chamber electronic nicotine delivery system with puff duration control and timed lockout and just-in-time adaptive intervention to treat nicotine dependence in cigarette smokers
WO2024010775A2 (fr) Système de dispositif d'administration pulmonaire dosée
US20140180238A1 (en) Pump Controlling Device That Obtains Parameter Values From Insulin Pump For Executing Functions
US12115349B2 (en) Systems and methods for managing diabetes
US20090326443A1 (en) Preparatory dispensation systems and methods
US20230067014A1 (en) Compensating for changes in potency of a medicament in a medicament delivery device

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19876729

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19876729

Country of ref document: EP

Kind code of ref document: A1